Bayer has completed its acquisition of Perfuse Therapeutics, adding a clinical-stage ophthalmology asset to its pharmaceutical pipeline. The deal gives Bayer full rights to PER-001, Perfuse’s lead intravitreal implant candidate, which is currently in Phase II clinical development for glaucoma and diabetic retinopathy. The acquisition marks a targeted expansion of Bayer’s presence in eye care, a field where the company already has established expertise and a broader strategic footprint.
Strengthening Bayer’s Ophthalmology Pipeline
The acquisition is designed to support Bayer’s strategy of building a stronger portfolio of medicines for diseases with significant unmet medical needs. Perfuse brings a differentiated approach to ocular disease through its work on ischemia-induced conditions, which are linked to impaired blood flow and can contribute to progressive vision loss. By bringing Perfuse into its organization, Bayer is adding a program that could complement its existing ophthalmology capabilities while broadening the company’s development opportunities in a market where durable and disease-focused therapies remain important.
Focus on PER-001
PER-001 is described as a first-in-class, sustained-release small molecule endothelin receptor antagonist delivered through an intravitreal implant. The therapy is being developed for glaucoma and diabetic retinopathy, two serious eye diseases that affect large patient populations and can lead to blindness if not properly managed. Its sustained-release design could offer a differentiated treatment profile by aiming to address underlying disease mechanisms while potentially reducing the burden associated with frequent interventions.
Transaction Value and Deal Structure
Bayer paid an upfront consideration of $300 million to complete the acquisition of Perfuse Therapeutics. The transaction has a total potential value of up to $2.45 billion, including the upfront payment and additional success-based milestone payments tied to future progress. The structure reflects the clinical and commercial potential Bayer sees in Perfuse’s lead asset, while linking a significant portion of the total value to development and achievement milestones.
Integration of Perfuse Therapeutics
Following completion of the transaction, Perfuse Therapeutics will be fully integrated into Bayer. The company is headquartered in South San Francisco, California, and also has research and development operations in Durham, North Carolina. Perfuse has focused on developing disease-modifying therapies for ocular diseases and has built its lead program around a proprietary sustained-release drug delivery platform intended to support new approaches for vision-threatening conditions.
Advisers and Corporate Context
BofA Securities served as Bayer’s exclusive financial adviser on the transaction, while Baker McKenzie acted as the company’s legal counsel. Perfuse was advised by Centerview Partners as exclusive financial adviser, with Goodwin Procter serving as legal counsel. Bayer said the acquisition fits its broader pharmaceutical strategy and reinforces its commitment to innovation in areas where scientific advances can address major health challenges.
Bayer’s acquisition of Perfuse Therapeutics gives the company a new clinical-stage asset in ophthalmology and expands its rights around a potential treatment for glaucoma and diabetic retinopathy. The deal also highlights Bayer’s continued use of targeted acquisitions to strengthen its pharmaceutical pipeline in areas with substantial patient need. As PER-001 continues through development, the transaction’s long-term significance will depend on whether the candidate can demonstrate meaningful clinical benefit and advance toward regulatory approval.